by The global genetic testing market is estimated to be valued at US$16.22 billion in 2023 and is expected to exhibit a CAGR of 12.4% over the forecast period of 2023-2030, according to a new report published by Coherent Market Insights.
Market Overview:
Genetic testing refers to the analysis of DNA, RNA, and other genetic material to identify changes or mutations that may be associated with various diseases or conditions. It plays a crucial role in personalized medicine, as it enables healthcare professionals to tailor treatments and preventive measures according to an individual’s genetic makeup. The market for genetic testing is driven by the growing prevalence of genetic disorders, increased awareness about the benefits of personalized medicine, and advancements in technology that have made genetic testing more accessible and affordable.
Market Key Trends:
One key trend in the genetic testing market is the increasing use of direct-to-consumer genetic testing kits. These kits allow consumers to easily collect a sample, such as saliva or a cheek swab, and send it to a laboratory for analysis. The results are then made available to the consumer, providing valuable information about their ancestry, genetic traits, and potential health risks. This trend has gained popularity due to its convenience and affordability, as well as the increasing interest among individuals in learning more about their genetic heritage and health. However, there are concerns about the accuracy and interpretation of the results, which may require further consultation with healthcare professionals.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the genetic testing market is moderate. While the market offers attractive growth potential, it is also highly regulated and requires significant investment in technology, infrastructure, and research. Moreover, established players hold strong brand recognition and have built customer trust over time, making it difficult for new entrants to gain market share.
Bargaining power of buyers: The bargaining power of buyers in the genetic testing market is high. This is primarily due to the availability of a wide range of testing options, resulting in intense competition among service providers. Buyers can easily switch between providers based on factors such as cost, accuracy, and turnaround time, exerting pressure on pricing and forcing companies to continuously innovate and improve their offerings.
Bargaining power of suppliers: The bargaining power of suppliers in the genetic testing market is low. This is because the market relies heavily on suppliers of genetic testing kits, equipment, and reagents. However, due to the presence of multiple suppliers and the availability of alternative products, companies have the ability to switch suppliers based on factors such as price, quality, and reliability.
Threat of new substitutes: The threat of new substitutes in the genetic testing market is low. Genetic testing plays a crucial role in diagnosing and managing various diseases and conditions, and there are currently no viable alternatives that offer the same level of accuracy and specificity. As a result, the demand for genetic testing is expected to remain strong in the foreseeable future.
Competitive rivalry: The competitive rivalry in the genetic testing market is intense. The market is characterized by the presence of numerous key players, both large and small, competing for market share. These players differentiate themselves based on factors such as test accuracy, coverage, price, and turnaround time. Additionally, ongoing advancements in technology and the increasing emphasis on personalized medicine are driving competition and innovation in the market.
Key Takeaways
The global genetic testing market is expected to witness high growth, exhibiting a CAGR of 12.4% over the forecast period of 2023-2030. This growth is attributed to the increasing prevalence of genetic disorders, the rising adoption of precision medicine, and advancements in sequencing technologies.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the genetic testing market. This can be attributed to factors such as a well-established healthcare infrastructure, increasing awareness about genetic testing, and favorable reimbursement policies.
Key players operating in the genetic testing market include 23&Me Inc., Qiagen NV, Eurofins Scientific, PerkinElmer Inc., Illumina Inc., Danaher Corporation, Myriad Genetics Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, BioRad Laboratories Inc., and DiaSorin S.p.A. These players are focusing on strategic collaborations, mergers and acquisitions, and product launches to strengthen their market position and expand their product offerings.
In conclusion, the genetic testing market is set to experience significant growth, driven by factors such as increasing prevalence of genetic disorders, growing adoption of precision medicine, and advancements in sequencing technologies. The market is highly competitive, with key players focusing on innovation and partnerships to maintain their market share. Furthermore, North America is expected to be the fastest-growing region in the market, driven by favorable reimbursement policies and a well-established healthcare infrastructure.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
